| Verfasst von: | Gerhards, Catharina [VerfasserIn] |
|---|---|
| Thiaucourt, Margot [VerfasserIn] | |
| Hetjens, Michael [VerfasserIn] | |
| Haselmann, Verena [VerfasserIn] | |
| Neumaier, Michael [VerfasserIn] | |
| Kittel, Maximilian [VerfasserIn] | |
| Titel: | Heterologous vector-mRNA based SARS-CoV-2 vaccination strategy appears superior to a homologous vector-based vaccination scheme in German healthcare workers regarding humoral SARS-CoV-2 response indicating a high boosting effect by mRNA vaccines |
| Verf.angabe: | Catharina Gerhards, Margot Thiaucourt, Michael Hetjens, Verena Haselmann, Michael Neumaier and Maximilian Kittel |
| E-Jahr: | 2023 |
| Jahr: | 19 March 2023 |
| Umfang: | 17 S. |
| Illustrationen: | Illustrationen |
| Fussnoten: | Gesehen am 31.07.2024 |
| Titel Quelle: | Enthalten in: Vaccines |
| Ort Quelle: | Basel : MDPI, 2013 |
| Jahr Quelle: | 2023 |
| Band/Heft Quelle: | 11(2023), 3 vom: März, Artikel-ID 701, Seite 1-17 |
| ISSN Quelle: | 2076-393X |
| Abstract: | Background: Longitudinal humoral SARS-CoV-2 (severe acute respiratory syndrome coronavirus type 2) immunity for up to 15 months due to vaccination, the efficacy of vaccination strategies (homologous, vector-vector versus heterologous, vector-mRNA), the influence of vaccination side effects, and the infection rate in German healthcare workers need to be investigated. Methods: In this study, 103 individuals vaccinated against SARS-CoV-2 were enrolled to examine their anti-SARS-CoV-2 anti-N- and anti-RBD/S1-Ig levels. A total of 415 blood samples in lithium heparin tubes were prospectively obtained, and a structured survey regarding medical history, type of vaccine, and vaccination reactions was conducted. Results: All participants demonstrated a humoral immune response, among whom no values decreased below the positivity cutoff. Five to six months after the third vaccination, three participants showed anti-RBD/S1 antibodies of less than 1000 U/mL. We observed higher levels for heterologous mRNA-/vector-based combinations compared to pure vector-based vaccination after the second vaccination, which is harmonized after a third vaccination with the mRNA-vaccine only in both cohorts. The incidence of vaccine breakthrough in a highly exposed cohort was 60.3%. Conclusion: Sustained long-term humoral immunity was observed, indicating the superiority of a heterologous mRNA-/vector-based combination compared to pure vector-based vaccination. There was longevity of anti-RBD/S1 antibodies of at least 4 and up to 7 months without external stimulus. Regarding vaccination reactogenity, the occurrence of local symptoms as pain at the injection site was increased after the first mRNA application compared to the vector-vector cohort with a general decrease in adverse events at later vaccination time points. Overall, a correlation between the humoral vaccination response and vaccination side effects was not observed. Despite the high prevalence of vaccine breakthroughs, these only occurred in the later course of the study when more infectious variants, which are, however, associated with milder courses, were present. These results provide insights into vaccine-related serologic responses, and the study should be expanded using additional vaccine doses and novel variants in the future. |
| DOI: | doi:10.3390/vaccines11030701 |
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt. kostenfrei: Volltext: https://doi.org/10.3390/vaccines11030701 |
| kostenfrei: Volltext: https://www.mdpi.com/2076-393X/11/3/701 | |
| DOI: https://doi.org/10.3390/vaccines11030701 | |
| Datenträger: | Online-Ressource |
| Sprache: | eng |
| Sach-SW: | anti-SARS-CoV-2 antibodies |
| antibody dynamics | |
| antibody kinetics | |
| humoral response post-vaccination | |
| longitudinal assessment | |
| serological immune response | |
| side effects | |
| vaccination breakthrough | |
| vaccination strategy | |
| K10plus-PPN: | 1897205376 |
| Verknüpfungen: | → Zeitschrift |